Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Strengthening of group management: New Commercial Director

Nordic Mining has appointed new Commercial Director to strengthen its sales and marketing operations going forward. Nordic Mining has appointed Maurice Kok as new Commercial Director effective from 1 August 2022. Mr. Kok has broad and international experience from sales and marketing of alloys and mineral products from Elkem, TiZir/Eramet and Kalbar Operations. In addition to sales management, Mr. Kok has specific experience from the mineral sands industry as well as business development and has been involved with mining projects at an early stage ahead of operations commencing. Mr.

iLOQ continues cooperation with Bayer 04 Leverkusen

iLOQ has signed an agreement to continue its partnership with Bundesliga football team – Bayer 04 Leverkusen. The partnership, which has already been in place for the 2021 – 2022 season, will be extended for the 2022 – 2023 season with the option to further extend cooperation into 2024. With exclusive status as a ‘Safety Partner’ of Bayer 04 Leverkusen, iLOQ belongs to a selected group of brands that make a productive contribution to the future of Bayer 04 Leverkusen. The cooperation also allows iLOQ to capitalize on its growth momentum in the important German market and boost

Nordea Bank Abp: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (BlackRock, Inc.)

Nordea Bank AbpStock exchange release – Major shareholder announcements27 April 2022 at 10.00 EET Nordea Bank Abp has on 26 April 2022 received a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which BlackRock, Inc.'s indirect shareholding of Nordea Bank Abp’s shares and voting rights has decreased below the threshold of 5 per cent on 25 April 2022. The total number of shares and voting rights in Nordea Bank Abp is 3,838,758,570. Total positions of BlackRock, Inc. and its funds according to the notification: +----------------+--------------

REBL Eats launches 6 new healthy plant-based on-the-go products as it expands internationally

Vegan ready meals are great for the planet but often have poor nutritional content – this Finnish startup wants to change the general perception of plant-based food and create tasty and nutritious meals for carnivores and vegans alike.Helsinki-based food impact startup REBL Eats  has announced the launch of six new plant-based breakfast items and sandwiches for consumers that want healthy shortcuts with no compromise on taste. This complements REBL’s existing portfolio of six ready-to-eat meals, which have sold over 150,000 units within nine months of launching in

NOTIFICATION OF MANAGERS’ AND CLOSELY RELATED PARTIES’ TRANSACTIONS WITH DAMPSKIBSSELSKABET NORDEN A/S’ SHARES IN CONNECTION WITH SHARE BUY-BACK PROGRAM

ANNOUNCEMENT NO. 104 - 27 MARCH 2022 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp participates by selling shares pro rata in order to maintain the current ownership of just under 32% of the shares in Dampskibsselskabet NORDEN A/S. The market will be informed accordingly – see the attached file and announcement no. 56/2022. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information:Thomas France, Investor Communications Partner, tel.: 3315 0451

Greenstat and Everfuel to develop Hydrogen Hub Agder

Herning, Denmark and Kristiansand, Norway, 27 April 2022 - Everfuel and Greenstat will in a joint venture establish a hydrogen hub in Kristiansand, Norway. Following up on the cooperation agreement entered in July 2021, Greenstat and Everfuel now announce that they are actively pursuing to establish a hydrogen hub in Kristiansand, Norway. In a collaboration between the two parties and the industry companies Elkem and Glencore Nikkelverk, they will work towards a hydrogen production facility in Kristiansand which will be accompanied by a distribution centre targeting the fast-growing

Interim Report, January – March 2022

PERIOD JANUARY 1 – MARCH 31, 2022 · Net sales of SEK 120 m (101 m) · Recurring revenues of SEK 77 m (66 m) · which corresponds to % of net sales 64 % (65 %) · EBITDA SEK 17 m (20 m) · EBITDA margin 14 % (19 %) · EBIT 4 m (6 m) · EBIT margin 3 % (6 %) · Net profit SEK 1 m (4 m) · Net profit margin 1 % (4 %) · EPS before dilution SEK 0.02 (0.08) · Cash flow from operating activities SEK 13 m (6 m) · ACV SEK 9 m (7 m) · ARR SEK 315 m (271 m)

Carbiotix signs first CarbiAXOS sales agreement with FibreHigh AB

Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has signed its first CarbiAXOS sales agreement with Swedish-based FibreHigh AB (“FibreHigh”). FibreHigh will have a right of first refusal to purchase 100% of all production capacity during 2022 and 2023 to support the launch of their Coffee Booster in the US market. This product will be launched in parallel with CarbiAXOS nutraceutical ingredient at the Microbiome Movement Human Nutrition Summit to be held in Boston, MA, USA, between the 8-9th of November 2022. Carbiotix will also focus on ramping up sales

From market hall to padel hall - one of Sweden’s largest recycling projects

The activities are in full swing at Östermalmshallen Padel in Mölnlycke. In spring 2021, the 2,000 square meter temporary market hall at Östermalmstorg square was taken down piece by piece like a large Lego set. Everything was packed into environmentally certified trucks, which were driven using Hydrotreated Vegetable Oil (HVO) fuel to the west coast. The temporary market hall has now been converted into a restaurant and padel hall right next to Wallenstam’s urban development project Mölnlycke Fabriker.The building, which has been nominated for and has won a number of awards for its design,

Zalaris further expands Asia Pacific Region and appoints Mike Ellis as Executive Vice President

With over two decades of providing our customers with global HR and payroll technology and services, we are thrilled to announce the further expansion of Zalaris within the APAC region as we establish local operations in Australia and Singapore.With a focus on strengthening our APAC region, this expansion will allow Zalaris to provide local support to our customers, cementing our position as a global leader for HR & Payroll technology and services. The decision to create local entities within these regions was made after extensive market research showing a strong buyers-market for local HR &

Valmet changes its financial reporting structure and provides comparative segment information for 2021

Valmet changes its financial reporting structure and provides comparative segment information for 2021 Valmet Oyj’s stock exchange release on April 27, 2022 at 9:30 a.m. EEST   Starting from January 1, 2022, Valmet has decided to change its financial reporting structure to better highlight the performance of Valmet’s businesses. The new reporting structure reflects Valmet’s operational model, anticipates the integration of Neles into Valmet, and is aligned with the way Valmet management follows the operational performance of Valmet’s businesses.   Valmet consists of three

Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action

Gothenburg, April 27, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation immuno-oncological treatments based on enhanced CAR T-cells and oncolytic viruses, announced today it has concluded preclinical proof-of-concept studies for its oncolytic virus ELC-201. The study results confirm ELC-201’s proposed mode-of-action.ELC-201 is a next-generation oncolytic virus that has been genetically modified to enable treatment of most cancers. The drug candidate has been armed with Elicera’s proprietary platform technology, iTANK,

Sleep Cycle interim report January – March 2022: Greater efficiency in marketing and continued growth resulted in improved operating margin

Net sales increased by 19.2% to SEK 50.1 million, equivalent to an increase of 21.3% adjusted for currency effects. Sales continued to increase from the previous quarter, mainly as a result of product investments that had a positive effect on the conversion rate and thereby drove new users. Greater efficiency allowed for lower investments in marketing with a sustained effect, which had positive effects on the operating margin during the quarter. The total number of users at the close of the period was 920,000, equivalent to a growth of 12.2%.First quarter summary (January-March 2022) ·

Sustainability in every strategic decision – Kappahl publishes its 2021 sustainability report today

Kappahl is publishing its 2021 sustainability report today. It sets out a new climate change strategy, a new code of conduct and new collaborations that clearly demonstrate its serious commitment to sustainability.“During the year, we brought Sandra Roos, Vice President Sustainability, into Kappahl’s Group Management team. With Sandra present, we can now incorporate sustainability considerations into all strategic decisions at an early stage,” says Kappahl’s CEO Elisabeth Peregi. “Placing my role in the management team enables us to progress more quickly on our sustainability journey.

Interim report January-March 2022

Alelion delivers on record order intake of 2021, increasing net sales by 66 percentDuring the first quarter, net sales increased to MSEK 24.2 (14.6), a growth of 66 percent. Order intake reached MSEK 8.5 (22.7), which is mostly attributable to the strong conclusion of 2021 where customers placed orders for a long time ahead. We are seeing customers adopting a different pattern of placing orders, now preferring larger contracts with blanket orders rather than smaller-volume orders in incremental steps. Overall, Alelion received orders for MSEK 184 during 2021. This is on par with the peak

Mentice publishes the company’s interim report for the period January–March 2022

A strong start for the year with continued overall growth· Our strong finish of 2021 is now followed by a first quarter of 2022 with considerable growth for both order intake and net sales. We increased the order book to 91.4 (72.9) MSEK compared to the end of 2021 (87.1) MSEK. · The orderbook now consists of 72% Annual Recurring Revenue based components adding up to 66 MSEK out of the total of 91.4 MSEK. · Net sales for the first quarter of 53.1 (32.3) MSEK, corresponding to an increase of 64.2% compared to the same period last year and the order intake was 54.4 (39.9) MSEK an

Cereno Scientific nominates drug candidate CS585 in PCA Program for continued development in cardiovascular disease

Cereno Scientific (XSAT: CRNO B) today announced that drug candidate CS585 has been nominated for continued development in the preclinical Prostacyclin Analog (PCA) Program after completing initial preclinical studies. The drug candidate was nominated after demonstrating highest potential in cardiovascular disease among a set of similar molecules. CS585 will continue in its preclinical development program with the aim to provide a better treatment for patients with cardiovascular disease.“I am pleased to see a candidate nominated in our PCA Program as it signifies progress and proven

2020 Bulkers Ltd. (2020) - Results for the first quarter of 2022

Hamilton, Bermuda, April 27, 2022 2020 Bulkers Ltd. (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three months ended March 31, 2022. Key events during the first quarter of 2022 -          The Company reported net profit of US$5.9 million and EBITDA of US$11.0 million for the first quarter of 2022.   -          Achieved average time charter equivalent earnings of approximately US$24,000, per day, gross.   -          The Company declared total cash distributions of US$0.26 per share for the months of January,

AFRY enters partnership with leading industrial cyber security company OTORIO

The partnership empowers AFRYs already strong commitment to being a market leader in the industrial cyber security field.As the cyber risk environment evolves, companies will need to keep up with threats to sustaining continuous safe operations. The partnership with OTORIO enables AFRY to deliver managed end-to-end OT (operational technology) risk management as well as zero-trust solutions that combat threats before they appear. It enables highly competitive and proactive OT-security services that permit industrial businesses to stay ahead of threats without interruptions or downtime. AFRY,

Enhertu granted BTD for HER2-low breast cancer

27 April 2022 07:00 BST Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer Based on DESTINY-Breast04 results where AstraZeneca and Daiichi Sankyo's Enhertu demonstrated a significant improvement in both progression-free survival and overall survival Enhertu has now been granted five Breakthrough Therapy Designations, including three in breast cancer and one in both lung and gastric cancers AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US

Alimak Group: Interim report January – March 2022

Focus on profitable growth · Continued profit improvement driven by revenue growth and improved gross margin · Continued strong order growth in Services · Organic revenue growth of 3% for the Group despite impacts from exiting of tower internals · Full speed to execute on phase three of the New Heights Programme, profitable growthFirst quarter 2022 · Order intake decreased by 2% to MSEK 1,053 (1,073) with an organic decrease of 9% · Service order intake increased 7% organically excluding Rental · Revenue increased by 11% to MSEK 936 (846) with an organic increase of

Interim report for first quarter 2022

A broader and stronger licensing business strengthens our position in infection preventionFirst quarter (January-March 2022) · Revenues amounted to SEK 55.2 (41.8) million, an increase of 32%, mainly through higher licensing revenues. Adjusted for currency the increase was 23%. · EBITDA amounted to SEK -4.0 (1.9) million with an EBITDA-margin of -7% (5%), a result of initiated investments in accordance with the focused growth strategy. · Operating profit amounted to SEK -16.6 (-9.7) million. · Net loss for the period amounted to SEK -16.5 (-10.5) million. Earnings per share

Alligator Bioscience AB: Interim report January–March 2022

A Quarter of Advancements for Alligator’s Key Assets “Q1 2022 was marked by many important advancements. We made progress with our key assets, mitazalimab and ATOR-1017, and ATOR-4066 and welcomed a new Chief Medical Officer to strengthen our medical leadership.” Søren Bregenholt, CEO Alligator Bioscience AB SIGNIFICANT EVENTS JANUARY-MARCH Pipeline: · In March, the Company successfully completed the Phase Ib part of the clinical study OPTIMIZE-1, and Phase II is now enrolling patients at the recommended dose of 900 µg/kg. · In January, Alligator initiated a sponsored

Quarterly Report Q1 2022

A strong start to the yearFirst quarter · Net sales increased by 22% to SEK 26,591 M (21,805), with organic growth of 14% (4) and acquired net growth of 0% (4) · Very strong organic sales growth in Americas, Entrance Systems and Global Technologies and strong growth in EMEIA, while organic sales declined in Asia Pacific · Three acquisitions with combined annual sales of about SEK 250 M were signed in the quarter · Operating income (EBIT) was SEK 4,001 M (3,187), corresponding to an operating margin of 15.0% (14.6) · Net income[ ]amounted to SEK 2,859 M (2,253) · Earnings

There are no items matching the current filter
There are no more items matching the current filter
Back to top